The ASCO Post

Zidesamtinib Demonstrates 94% Response Rate in TKI-Naive Patients With Advanced ROS1-Positive NSCLC

New results from the global phase I/II ARROS-1 trial showed clinically meaningful activity with the ROS1 selective inhibitor zidesamtinib in patients with advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

First-Line Trastuzumab Deruxtecan Prolongs PFS in HER2-Mutant NSCLC

Trastuzumab deruxtecan significantly improved progression-free survival (PFS) over pembrolizumab plus platinum-based chemotherapy for patients with advanced or metastatic HER2-mutant NSCLC who were being treated in the first-line setting, according to findings from the phase III DESTINY-Lung04 trial.

Zipalertinib Added to Chemotherapy Improves Progression-Free Survival in First-Line EGFR Exon 20 Mutation–Positive NSCLC

The addition of zipalertinib to platinum/pemetrexed chemotherapy led to a significant improvement in PFS in patients with advanced NSCLC harboring an EGFR exon 20 insertion mutation, according to phase III findings.

NEWS FROM ASCO AI IN ONCOLOGY

Two Studies Evaluate AI-Based TIL Scoring for Breast Cancer Prognostication

High-Risk Prostate Cancer: GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT

In the GETUG-AFU 18 study of patients with high-risk prostate cancer receiving long-term androgen-deprivation therapy (ADT), dose-escalated radiotherapy was superior to conventional-dose radiotherapy, although the findings should be interpreted with caution, wrote investigators, because of the low number of events observed.

OPTIMUM Trial Reports 5-Year Outcomes With Extended Therapy in High-Risk Multiple Myeloma

Investigators report long-term follow-up from the OPTIMUM trial examining a risk-adapted, extended treatment strategy for patients with newly diagnosed high-risk multiple myeloma.

FDA Approves New Labeling of ROS1 Inhibitor in TKI-Naive Advanced NSCLC

The U.S. Food and Drug Administration (FDA) has approved updated labeling of taletrectinib (Ibtrozi), an oral, CNS-active, selective next-generation ROS1 inhibitor therapy for NSCLC, reflecting a median duration of response of 49.7 months in tyrosine kinase inhibitor (TKI)-naive patients in the TRUST-I trial, and validating more than 4 years of sustained clinical benefit.